Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis.
Haroon
H
Sawar
Luis R
LR
Espinoza
Abraham
A
Gedalia
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D001171:Arthritis, Juvenile / Q000150:complications*; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000276:immunology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007154:Immune System Diseases / Q000209:etiology* / Q000276:immunology; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000276:immunology; D008262:Macrophage Activation / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology; D013577:Syndrome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept